Sep 11, 2023 / 11:00AM GMT
Boobalan Pachaiyappan - H.C. Wainwright & Co., LLC - Analyst
Hello, everyone. My name is Boobalan Pachaiyappan. I'm H.C. Wainwright Vice President and senior biopharma analyst. With me today is Dr. Hans Schambye, Chief Executive Officer of Galecto.
For investors new to the story, Galecto is a clinical-stage biotech focused on developing novel drugs for fibrosis and cancers. Hans, welcome to the show.
Hans Schambye - Galecto, Inc. - CEO
Thanks a lot, Boobalan. Happy to be here.
Boobalan Pachaiyappan - H.C. Wainwright & Co., LLC - Analyst
Great. So before getting started, I would like to make a disclosure here. I cover Galecto with my colleague, Dr. Ram Selvaraju, who's the Managing Director at the firm. Our recommendation for Galecto is buy rating and $2 price target.
Questions and Answers:
Boobalan Pachaiyappan - H.C. Wainwright & Co., LLC - AnalystHans, with the formalities out of the way, let's just begin our discussion with IPF program. So